Two cases of idiopathic multicentric Castleman disease with nephrotic syndrome treated with tocilizumab | Zendy

Norihiro Furutera | Zendy; Naoya Fukunaga | Zendy; Jun Okita | Zendy; Tomoko Suzuki | Zendy; Yuko Suenaga | Zendy; Yuzo Oyama | Zendy; Kohei Aoki | Zendy; Akihiro Fukuda | Zendy; Takeshi Nakata | Zendy; Noriko Uesugi | Zendy; Tsutomu Daa | Zendy; Satoshi Hisano | Zendy; Hirotaka Shibata | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Two cases of idiopathic multicentric Castleman disease with nephrotic syndrome treated with tocilizumab

Author(s) -

Norihiro Furutera,

Naoya Fukunaga,

Jun Okita,

Tomoko Suzuki,

Yuko Suenaga,

Yuzo Oyama,

Kohei Aoki,

Akihiro Fukuda,

Takeshi Nakata,

Noriko Uesugi,

Tsutomu Daa,

Satoshi Hisano,

Hirotaka Shibata

Publication year - 2020

Publication title -

cen case reports

Language(s) - English

Resource type - Journals

ISSN - 2192-4449

DOI - 10.1007/s13730-020-00511-8

Subject(s) - tocilizumab , medicine , nephrotic syndrome , renal biopsy , proteinuria , nephrology , gastroenterology , nephropathy , amyloidosis , pathology , biopsy , kidney , disease , endocrinology , diabetes mellitus

We report two cases of idiopathic multicentric Castleman disease (iMCD) with nephrotic syndrome (NS) treated with tocilizumab. Case 1 was a 58-year-old man diagnosed with iMCD prior to the onset of NS. Renal biopsy revealed membranous nephropathy, which was considered to be secondary membranous nephropathy associated with iMCD. Case 2 was a 49-year-old woman diagnosed with iMCD prior to NS. Renal biopsy revealed renal amyloidosis positive for Congo red staining and amyloid A protein immunostaining. In both the cases, the proteinuria improved after the initiation of glucocorticoid and tocilizumab therapy. Tocilizumab may be a good therapeutic choice for iMCD with NS.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research